Howard Taylor Ricketts Laboratory, Argonne National Laboratory, Argonne, Illinois, USA.
Infect Immun. 2012 Apr;80(4):1572-82. doi: 10.1128/IAI.05637-11. Epub 2012 Jan 17.
Current efforts to develop plague vaccines focus on LcrV, a polypeptide that resides at the tip of type III secretion needles. LcrV-specific antibodies block Yersinia pestis type III injection of Yop effectors into host immune cells, thereby enabling phagocytes to kill the invading pathogen. Earlier work reported that antibodies against Y. pestis LcrV cannot block type III injection by Yersinia enterocolitica strains and suggested that lcrV polymorphisms may provide for escape from LcrV-mediated plague immunity. We show here that polyclonal or monoclonal antibodies raised against Y. pestis KIM D27 LcrV (LcrV(D27)) bind LcrV from Y. enterocolitica O:9 strain W22703 (LcrV(W22703)) or O:8 strain WA-314 (LcrV(WA-314)) but are otherwise unable to block type III injection by Y. enterocolitica strains. Replacing the lcrV gene on the pCD1 virulence plasmid of Y. pestis KIM D27 with either lcrV(W22703) or lcrV(WA-314) does not affect the ability of plague bacteria to secrete proteins via the type III pathway, to inject Yops into macrophages, or to cause lethal plague infections in mice. LcrV(D27)-specific antibodies blocked type III injection by Y. pestis expressing lcrV(W22703) or lcrV(WA-314) and protected mice against intravenous lethal plague challenge with these strains. Thus, although antibodies raised against LcrV(D27) are unable to block the type III injection of Y. enterocolitica strains, expression of lcrV(W22703) or lcrV(WA-314) in Y. pestis did not allow these strains to escape LcrV-mediated plague protective immunity in the intravenous challenge model.
目前,开发鼠疫疫苗的工作重点是 LcrV,这是一种位于 III 型分泌针尖端的多肽。LcrV 特异性抗体可阻止鼠疫耶尔森氏菌将 Yop 效应物注入宿主免疫细胞,从而使吞噬细胞能够杀死入侵的病原体。早期的研究报告称,针对鼠疫耶尔森氏菌 LcrV 的抗体不能阻止肠型耶尔森氏菌菌株的 III 型注射,并表明 lcrV 多态性可能提供逃避 LcrV 介导的鼠疫免疫的途径。我们在这里表明,针对鼠疫耶尔森氏菌 KIM D27 的多克隆或单克隆抗体针对肠型耶尔森氏菌 O:9 菌株 W22703(LcrV(W22703))或 O:8 菌株 WA-314(LcrV(WA-314))的 LcrV 结合,但否则无法阻止肠型耶尔森氏菌菌株的 III 型注射。用肠型耶尔森氏菌 KIM D27 的 pCD1 毒力质粒上的 lcrV(W22703)或 lcrV(WA-314)替换 lcrV 基因不会影响鼠疫菌通过 III 型途径分泌蛋白、将 Yops 注入巨噬细胞或导致致命的鼠疫感染的能力在小鼠中。LcrV(D27)特异性抗体阻断了表达 lcrV(W22703)或 lcrV(WA-314)的鼠疫耶尔森氏菌的 III 型注射,并保护小鼠免受这些菌株的静脉内致死性鼠疫挑战。因此,尽管针对 LcrV(D27)的抗体无法阻断肠型耶尔森氏菌菌株的 III 型注射,但 lcrV(W22703)或 lcrV(WA-314)在鼠疫耶尔森氏菌中的表达并没有使这些菌株在静脉内挑战模型中逃避 LcrV 介导的鼠疫保护性免疫。